Néovacs announces that it has raised €0.2 million through the issue of OCEANE-BSA, with a par value of E200,000, subscribed by the European High Growth Opportunities Securitization Fund.

The net proceeds of this operation (E192,000) will be used to finance the Kinoïde allergy research program and to strengthen the company's investment capacities, both in the development of drug candidates (BioTech) and medical devices (MedTech).

The OCEANE-BSA issue announced today gives rise to the issue of 529,100 warrants, which will be retroceded to Neovacs for cancellation, and could give rise to the creation of 1,291,990 new shares based on the last quoted price.

All OCEANE-BSA issues to date could give rise to the creation of 4,392,765 new shares based on the last quoted price.

Copyright (c) 2024 CercleFinance.com. All rights reserved.